Vedolizumab is a humanized monoclonal antibody and one of the safest biologics for the treatment ofboth forms of inflammatory bowel disease(IBD)-Crohn’s disease and ulcerative colitis.It targets theα4β7 integrinand...Vedolizumab is a humanized monoclonal antibody and one of the safest biologics for the treatment ofboth forms of inflammatory bowel disease(IBD)-Crohn’s disease and ulcerative colitis.It targets theα4β7 integrinand blocks leukocyte trafficking to the gut.Regardless of its efficacy in many patients,non-response to vedolizumabtreatment poses a significant clinical challenge.In this review,we synthesize recent findings on genomic,transcriptomic,proteomic,and cellular biomarkers of vedolizumab response,emphasizing their roles in predicting therapeutic outcomesand understanding non-responsiveness.Key insights include the identification of epigenetic and transcriptomicsignatures,the involvement of Th17 and IL-6 signaling,and the role of baseline inflammatory markers like albumin.Discrepancies in findings highlight the complexity of biomarker discovery and underscore the need for standardized,multiparametric approaches to refine personalized treatment strategies.By bridging knowledge gaps in vedolizumabresponsiveness,this review aims to advance biomarker-driven decision-making and improve outcomes for patientswith IBD.展开更多
The miniature chromosome maintenance(MCM)complex is a group of proteins that are essential for DNA replication licensing and control of cell cycle progression from G1 to S phase.Recent studies suggest that MCM7 is ove...The miniature chromosome maintenance(MCM)complex is a group of proteins that are essential for DNA replication licensing and control of cell cycle progression from G1 to S phase.Recent studies suggest that MCM7 is overexpressed and amplified in a variety of human malignancies.MCM7 genome sequence contains a cluster of miRNA that has been shown to downregulate expression of several tumor suppressors including p21,E2F1,BIM and pTEN.The oncogenic potential of MCM7 and its embedded miRNA has been demonstrated vigorously in in vitro experiments and in animal models,and they appear to cooperate in initiation of cancer.MCM7 protein also serves as a critical target for oncogenic signaling pathways such as androgen receptor signaling,or tumor suppressor pathways such as integrinα7 or retinoblastoma signaling.This review analyzes the transforming activity and signaling of MCM7,oncogenic function of miRNA cluster that is embedded in the MCM7 genome,and the potential of gene therapy that targets MCM7.展开更多
Ischemia/reperfusion is known to greatly increase oxidative stress in the penumbra,which results in brain damage.Integrinαvβ3 is selectively up-regulated with ischemic injury to the brain and remains elevated throug...Ischemia/reperfusion is known to greatly increase oxidative stress in the penumbra,which results in brain damage.Integrinαvβ3 is selectively up-regulated with ischemic injury to the brain and remains elevated throughout reperfusion.We determined whether or not a new compound biotinylated-LXW7-ceria nanoparticle(Ce NP)(b LXW7-Ce NP)plays a role in brain protection in the rat model of middle cerebral artery occlusion/reperfusion and shows better effects than Ce NPs alone in improving the outcomes of focal oxidative stress and apoptosis more effectively.Male Sprague-Dawley rats were subjected to focal cerebral ischemia for 2 h followed by a 24-h reperfusion.Drug treatment was intravenously administered via the caudal vein 1 h after occlusion.Rats were randomly divided into the following 4 groups:b LXW7-Ce NP treatment group(0.5 mg/kg);Ce NP treatment group(0.5 mg/kg);control saline group;and sham group.Brains were harvested 24 h after reperfusion,and the neurologic deficit scores,infarction volume,blood-brain barrier(BBB)disruption,and the level of oxidative stress and apoptosis were determined.Results showed that the b LXW7-Ce NP and Ce NP treatments could improve neurologic deficit scores,infarction volume,BBB disruption,and the level of oxidative stress and apoptosis.Compound b LXW7-Ce NP treatment exhibited better effects than Ce Np treatment and showed remarkable statistical differences in the infarction volume,the degree of BBB breakdown,the apoptosis and oxidative stress,apart from neurologic deficit scores.Thus,we concluded that b LXW7-Ce NP protects against acute cerebral ischemia/reperfusion injury.BLXW7,as a ligand of integrinαvβ3,may be able to effectively localize the anti-oxidant Ce NPs to the ischemic penumbra region,which may provide more adequate opportunities for Ce NPs to exert anti-oxidative stress effects and subsequently reduce apoptosis in acute cerebral ischemia/reperfusion.展开更多
HIV-1 envelope glycoprotein is reported to interact with α4β7, an integrin mediating the homing of lymphocytes to gut-associated lymphoid tissue, but the significance of α4β7 in HIV-1 infection remains controversi...HIV-1 envelope glycoprotein is reported to interact with α4β7, an integrin mediating the homing of lymphocytes to gut-associated lymphoid tissue, but the significance of α4β7 in HIV-1 infection remains controversial. Here, using HIV-1 strain Ba L, the gp120 of which was previously shown to be capable of interacting with α4β7, we demonstrated that α4β7 can mediate the binding of whole HIV-1 virions to α4β7-expressing transfectants. We further constructed a cell line stably expressing α4β7 and confirmed the α4β7-mediated HIV-1 binding. In primary lymphocytes with activated α4β7 expression, we also observed significant virus binding which can be inhibited by an anti-α4β7 antibody. Moreover, we investigated the impact of antagonizing α4β7 on HIV-1 infection of primary CD4+ T cells. In α4β7-activated CD4+ T cells, both anti-α4β7 antibodies and introduction of shorthairpin RNAs specifically targeting α4β7 resulted in a decreased HIV-1 infection. Our findings indicate that α4β7 may serve as an attachment factor at least for some HIV-1 strains. The established approach provides a promising means for the investigation of other viral strains to understand the potential roles of α4β7 in HIV-1 infection.展开更多
Medical treatment has progressed significantly over the past decade towards achieving and maintaining clinical remission in patients with refractory ulcerative colitis(UC). Proposed mediators of inflammation in UC inc...Medical treatment has progressed significantly over the past decade towards achieving and maintaining clinical remission in patients with refractory ulcerative colitis(UC). Proposed mediators of inflammation in UC include pro-inflammatory cytokines such as tumor necrosis factor-α(TNF-α) and interleukin-2, and the cellsurface adhesive molecule integrin α4β7. Conventional therapeutics for active UC include 5-aminosalicylic acid, corticosteroids and purine analogues(azathioprine and 6-mercaptopurine). Patients who fail to respond to conventional therapy are treated with agents such as the calicineurin inhibitors cyclosporine and tacrolimus, the TNF-α inhibitors infliximab or adalimumab, or a neutralizing antibody(vedolizumab) directed against integrin α4β7. These therapeutic agents are of benefit for patients with refractory UC, but are not universally effective. Our recent research on TNF-α shedding demonstrated that inhibition of annexin(ANX) A2 may be a new therapeutic strategy for the prevention of TNF-α shedding during inflammatory bowel disease(IBD) inflammation. In this review, we provide an overview of therapeutic treatments that are effective and currently available for UC patients, as well as some that are likely to be available in the near future. We also propose the potential of ANX A2 as a new molecular target for IBD treatment.展开更多
基金supported by the Slovenian Research and Innovation Agency(ARIS)—Young Researcher Program(contract no.104-04/TK–6811)Research Core Funding P3-0427.
文摘Vedolizumab is a humanized monoclonal antibody and one of the safest biologics for the treatment ofboth forms of inflammatory bowel disease(IBD)-Crohn’s disease and ulcerative colitis.It targets theα4β7 integrinand blocks leukocyte trafficking to the gut.Regardless of its efficacy in many patients,non-response to vedolizumabtreatment poses a significant clinical challenge.In this review,we synthesize recent findings on genomic,transcriptomic,proteomic,and cellular biomarkers of vedolizumab response,emphasizing their roles in predicting therapeutic outcomesand understanding non-responsiveness.Key insights include the identification of epigenetic and transcriptomicsignatures,the involvement of Th17 and IL-6 signaling,and the role of baseline inflammatory markers like albumin.Discrepancies in findings highlight the complexity of biomarker discovery and underscore the need for standardized,multiparametric approaches to refine personalized treatment strategies.By bridging knowledge gaps in vedolizumabresponsiveness,this review aims to advance biomarker-driven decision-making and improve outcomes for patientswith IBD.
文摘The miniature chromosome maintenance(MCM)complex is a group of proteins that are essential for DNA replication licensing and control of cell cycle progression from G1 to S phase.Recent studies suggest that MCM7 is overexpressed and amplified in a variety of human malignancies.MCM7 genome sequence contains a cluster of miRNA that has been shown to downregulate expression of several tumor suppressors including p21,E2F1,BIM and pTEN.The oncogenic potential of MCM7 and its embedded miRNA has been demonstrated vigorously in in vitro experiments and in animal models,and they appear to cooperate in initiation of cancer.MCM7 protein also serves as a critical target for oncogenic signaling pathways such as androgen receptor signaling,or tumor suppressor pathways such as integrinα7 or retinoblastoma signaling.This review analyzes the transforming activity and signaling of MCM7,oncogenic function of miRNA cluster that is embedded in the MCM7 genome,and the potential of gene therapy that targets MCM7.
基金supported by grants from Shenzhen Science and Technology Innovation Committee(No.JCYJ20140415162543033)Startup Fund Project of Inner Mongolia University(No.21300-5145152)+1 种基金Key Project of Education Department of Inner Mongolia(No.NJZZ16015)the Natural Science Foundation of Inner Mongolia(No.2016MS0216)
文摘Ischemia/reperfusion is known to greatly increase oxidative stress in the penumbra,which results in brain damage.Integrinαvβ3 is selectively up-regulated with ischemic injury to the brain and remains elevated throughout reperfusion.We determined whether or not a new compound biotinylated-LXW7-ceria nanoparticle(Ce NP)(b LXW7-Ce NP)plays a role in brain protection in the rat model of middle cerebral artery occlusion/reperfusion and shows better effects than Ce NPs alone in improving the outcomes of focal oxidative stress and apoptosis more effectively.Male Sprague-Dawley rats were subjected to focal cerebral ischemia for 2 h followed by a 24-h reperfusion.Drug treatment was intravenously administered via the caudal vein 1 h after occlusion.Rats were randomly divided into the following 4 groups:b LXW7-Ce NP treatment group(0.5 mg/kg);Ce NP treatment group(0.5 mg/kg);control saline group;and sham group.Brains were harvested 24 h after reperfusion,and the neurologic deficit scores,infarction volume,blood-brain barrier(BBB)disruption,and the level of oxidative stress and apoptosis were determined.Results showed that the b LXW7-Ce NP and Ce NP treatments could improve neurologic deficit scores,infarction volume,BBB disruption,and the level of oxidative stress and apoptosis.Compound b LXW7-Ce NP treatment exhibited better effects than Ce Np treatment and showed remarkable statistical differences in the infarction volume,the degree of BBB breakdown,the apoptosis and oxidative stress,apart from neurologic deficit scores.Thus,we concluded that b LXW7-Ce NP protects against acute cerebral ischemia/reperfusion injury.BLXW7,as a ligand of integrinαvβ3,may be able to effectively localize the anti-oxidant Ce NPs to the ischemic penumbra region,which may provide more adequate opportunities for Ce NPs to exert anti-oxidative stress effects and subsequently reduce apoptosis in acute cerebral ischemia/reperfusion.
基金supported by National Natural Science Foundation of China Grant 81273250Ministry of Science and Technology of China Grants 2013ZX10001005003-002 and 2012ZX10001006-002
文摘HIV-1 envelope glycoprotein is reported to interact with α4β7, an integrin mediating the homing of lymphocytes to gut-associated lymphoid tissue, but the significance of α4β7 in HIV-1 infection remains controversial. Here, using HIV-1 strain Ba L, the gp120 of which was previously shown to be capable of interacting with α4β7, we demonstrated that α4β7 can mediate the binding of whole HIV-1 virions to α4β7-expressing transfectants. We further constructed a cell line stably expressing α4β7 and confirmed the α4β7-mediated HIV-1 binding. In primary lymphocytes with activated α4β7 expression, we also observed significant virus binding which can be inhibited by an anti-α4β7 antibody. Moreover, we investigated the impact of antagonizing α4β7 on HIV-1 infection of primary CD4+ T cells. In α4β7-activated CD4+ T cells, both anti-α4β7 antibodies and introduction of shorthairpin RNAs specifically targeting α4β7 resulted in a decreased HIV-1 infection. Our findings indicate that α4β7 may serve as an attachment factor at least for some HIV-1 strains. The established approach provides a promising means for the investigation of other viral strains to understand the potential roles of α4β7 in HIV-1 infection.
基金Supported by Grant-in-Aid for Scientific Research(C)from Japan Society for the Promotion of Science,No.25460957
文摘Medical treatment has progressed significantly over the past decade towards achieving and maintaining clinical remission in patients with refractory ulcerative colitis(UC). Proposed mediators of inflammation in UC include pro-inflammatory cytokines such as tumor necrosis factor-α(TNF-α) and interleukin-2, and the cellsurface adhesive molecule integrin α4β7. Conventional therapeutics for active UC include 5-aminosalicylic acid, corticosteroids and purine analogues(azathioprine and 6-mercaptopurine). Patients who fail to respond to conventional therapy are treated with agents such as the calicineurin inhibitors cyclosporine and tacrolimus, the TNF-α inhibitors infliximab or adalimumab, or a neutralizing antibody(vedolizumab) directed against integrin α4β7. These therapeutic agents are of benefit for patients with refractory UC, but are not universally effective. Our recent research on TNF-α shedding demonstrated that inhibition of annexin(ANX) A2 may be a new therapeutic strategy for the prevention of TNF-α shedding during inflammatory bowel disease(IBD) inflammation. In this review, we provide an overview of therapeutic treatments that are effective and currently available for UC patients, as well as some that are likely to be available in the near future. We also propose the potential of ANX A2 as a new molecular target for IBD treatment.
